Abbott Laboratories (ABT)

NYSE · Abbott Park, Illinois, USA · Founded 1888 · CEO Robert Ford

Valuation summary

$126.93 fair value versus $103.87 in the market, a difference of +22.2%. Rated Buy.

Fair value per share$126.93
Current share price$103.87
Upside / downside+22.2%
Bear case$82.50
Bull case$191.70
Discount rate (WACC)8.4%
Terminal growth2.60%
Market capitalisation$180B
EV / Sales3.9x

About Abbott Laboratories

Founded in 1888 by physician Wallace Abbott. Robert Ford has been CEO since 2020. Abbott spans four quite different businesses: medical devices, diagnostics, established pharmaceuticals sold mainly in emerging markets, and nutrition products including Similac and Ensure. The acquisition of Exact Sciences added Cologuard and a cancer screening franchise to diagnostics. Its most important growth asset is FreeStyle Libre, a continuous glucose monitor that has become the standard of care for diabetes management and is expanding into non-insulin-dependent users.

Investment case

  • FreeStyle Libre is a category leader in a large and still-underpenetrated diabetes market.
  • Genuine diversification across four businesses smooths the earnings profile.
  • Structural heart and electrophysiology device franchises are growing well above company average.

Key risks

  • COVID testing revenue has fully normalised, creating a multi-year comparison drag.
  • Ongoing litigation relating to preterm infant formula creates a tail risk that is hard to size.
  • Dexcom competes directly and aggressively in continuous glucose monitoring.

Recent developments

Revenue by segment

Medical Devices45%
Diagnostics22%
Nutrition18%
Established Pharmaceuticals15%

Five-year forecast

RevenueFree cash flow
Year 1$52.8B$9.1B
Year 2$58.0B$10.0B
Year 3$63.6B$10.9B
Year 4$69.7B$11.9B
Year 5$76.2B$13.0B

What the street says

Viewed as a steady, defensive compounder. Rothschild & Co Redburn upgraded the shares to Buy in October 2026, arguing Exact Sciences strengthens diagnostics growth and margins; the $385m settlement in September 2026 closed the government's 2022 formula recall case, leaving preterm formula litigation and Libre growth as the main swing factors.

Comparable companies: MDT · AZN · TMO · SNY · IDXX · SYK · ISRG · A

Open the interactive model, price chart and sensitivity grid →